Nothing Special   »   [go: up one dir, main page]

HRP20240823T1 - Farmaceutski pripravak, namijenjen upotrebi u liječenju ili sprječavanju bolesti povezane s c5 i postupak liječenja ili sprječavanja bolesti povezane s c5 - Google Patents

Farmaceutski pripravak, namijenjen upotrebi u liječenju ili sprječavanju bolesti povezane s c5 i postupak liječenja ili sprječavanja bolesti povezane s c5 Download PDF

Info

Publication number
HRP20240823T1
HRP20240823T1 HRP20240823TT HRP20240823T HRP20240823T1 HR P20240823 T1 HRP20240823 T1 HR P20240823T1 HR P20240823T T HRP20240823T T HR P20240823TT HR P20240823 T HRP20240823 T HR P20240823T HR P20240823 T1 HRP20240823 T1 HR P20240823T1
Authority
HR
Croatia
Prior art keywords
phase
subcutaneous
pharmaceutical preparation
administration
dose
Prior art date
Application number
HRP20240823TT
Other languages
English (en)
Inventor
Kenji SHINOMIYA
Keisuke GOTANDA
Jun-ichi NISHIMURA
Erica WINTER
Joy C. HSU
Original Assignee
Chugai Seiyaku Kabushiki Kaisha
F. Hoffmann-La Roche Ag
Osaka University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Chugai Seiyaku Kabushiki Kaisha, F. Hoffmann-La Roche Ag, Osaka University filed Critical Chugai Seiyaku Kabushiki Kaisha
Publication of HRP20240823T1 publication Critical patent/HRP20240823T1/hr

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183Amino acids, e.g. glycine, EDTA or aspartame
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0019Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0019Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A61K9/0021Intradermal administration, e.g. through microneedle arrays, needleless injectors
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/08Solutions
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/02Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • A61P37/06Immunosuppressants, e.g. drugs for graft rejection
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00Drugs for disorders of the blood or the extracellular fluid
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06Antianaemics
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/505Medicinal preparations containing antigens or antibodies comprising antibodies
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/54Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/545Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/20Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/70Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/70Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/90Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/90Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Dermatology (AREA)
  • Diabetes (AREA)
  • Transplantation (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Hematology (AREA)
  • Rheumatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Claims (2)

1. Farmaceutski pripravak, formuliran za supkutanu injekciju koja sadrži protutijelo protiv C5, koji sadrži VH slijed SEQ ID NO: 2 i VL slijed SEQ ID NO: 6, naznačen time što je namijenjen upotrebi u postupku liječenja ili sprječavanja bolesti povezane s C5, koju se bira iz skupine koju čine reumatoidni artritis (RA); lupozni nefritis; ishemijsko-reperfuzijska ozljeda; paroksiumalna noćna hemoglobinurija (PNH), atipični hemolitički uremijski sindrom (aHUS), bolest gustih naslaga (DDD); degeneracija makule; hemoliza, povišeni jetreni enzimi, te sindrom niskih trombocita (HELLP); trombotska trombocitopenična purpura (UP); spontani gubitak fetusa; oligoimuni vaskulitis; bulozna epidermoliza; recidivirajući gubitak fetusa; multipla skleroza (MS); traumatska ozljeda mozga; ozljeda koja je posljedica infarkta miokarda, kardiopulmonalna premosnica ili hemodijaliza; refraktorna generalizirana miastenija gravis (gMG), te neuromijelitis očnog živca (NMO), gdje se pripravak supkutano primijenjuje u dvije faze nakon primjene farmaceutskog pripravka formuliranog za intravensku injekciju koja sadrži protutijelo protiv C5, gdje u obje faze supkutanih primjena postoji interval između svake dvije supkutane primjene, gdje svaka faza sadrži najmanje jedan interval, gdje je doza protutijela intravenske primjene 1000 mg, gdje se prvu supkutanu primjenu prve faze primijenjuje 0 do 8 dana nakon konačne primjene intravenski primijenjenog farmaceutskog pripravka, gdje je doza protutijela u supkutanoj primjeni prve faze 170 mg ili 340 mg, gdje se farmaceutski pripravak primijenjuje u prvoj fazi jednom svakog tjedna (tjedno), te gdje se farmaceutski pripravak namijenjen supkutana primjena primijenjuje u drugoj fazi četiri puta tjedno, u dozi od 680 mg.
2. Farmaceutski pripravak namijenjen upotrebi u skladu s patentnim zahtjevom 1, naznačen time što je broj supkutanih primjena u prvoj fazi 1 do 12.
HRP20240823TT 2018-08-01 2019-08-01 Farmaceutski pripravak, namijenjen upotrebi u liječenju ili sprječavanju bolesti povezane s c5 i postupak liječenja ili sprječavanja bolesti povezane s c5 HRP20240823T1 (hr)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201862713211P 2018-08-01 2018-08-01
US201862764952P 2018-08-17 2018-08-17
US201862760204P 2018-11-13 2018-11-13
PCT/JP2019/030283 WO2020027279A1 (en) 2018-08-01 2019-08-01 A pharmaceutical composition for use in the treatment or prevention of a c5-related disease and a method for treating or preventing a c5-related disease
EP19755447.0A EP3829628B1 (en) 2018-08-01 2019-08-01 A pharmaceutical composition for use in the treatment or prevention of a c5-related disease

Publications (1)

Publication Number Publication Date
HRP20240823T1 true HRP20240823T1 (hr) 2024-09-27

Family

ID=67660420

Family Applications (1)

Application Number Title Priority Date Filing Date
HRP20240823TT HRP20240823T1 (hr) 2018-08-01 2019-08-01 Farmaceutski pripravak, namijenjen upotrebi u liječenju ili sprječavanju bolesti povezane s c5 i postupak liječenja ili sprječavanja bolesti povezane s c5

Country Status (21)

Country Link
US (1) US20210301004A1 (hr)
EP (2) EP3829628B1 (hr)
JP (3) JP6672516B2 (hr)
KR (5) KR20200033225A (hr)
CN (1) CN112512563A (hr)
AU (2) AU2019315213B2 (hr)
BR (1) BR112021001655A2 (hr)
CA (1) CA3107618A1 (hr)
CR (1) CR20210103A (hr)
DE (1) DE112019003835T5 (hr)
ES (1) ES2980137T3 (hr)
HR (1) HRP20240823T1 (hr)
HU (1) HUE067057T2 (hr)
IL (1) IL280475A (hr)
MX (1) MX2021000516A (hr)
PH (1) PH12021550226A1 (hr)
PL (1) PL3829628T3 (hr)
RS (1) RS65630B1 (hr)
SG (1) SG10202002898RA (hr)
TW (2) TWI704157B (hr)
WO (1) WO2020027279A1 (hr)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007114319A1 (ja) 2006-03-31 2007-10-11 Chugai Seiyaku Kabushiki Kaisha 抗体の血中動態を制御する方法
US9096651B2 (en) 2007-09-26 2015-08-04 Chugai Seiyaku Kabushiki Kaisha Method of modifying isoelectric point of antibody via amino acid substitution in CDR
JP4954326B2 (ja) 2008-04-11 2012-06-13 中外製薬株式会社 複数分子の抗原に繰り返し結合する抗原結合分子
SG190727A1 (en) 2010-11-30 2013-07-31 Chugai Pharmaceutical Co Ltd Antigen-binding molecule capable of binding to plurality of antigen molecules repeatedly
RU2746356C2 (ru) 2014-12-19 2021-04-12 Чугаи Сейяку Кабусики Кайся Антитела к с5 и способы их применения
KR20230079499A (ko) 2016-08-05 2023-06-07 추가이 세이야쿠 가부시키가이샤 Il-8 관련 질환의 치료용 또는 예방용 조성물

Family Cites Families (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL85035A0 (en) 1987-01-08 1988-06-30 Int Genetic Eng Polynucleotide molecule,a chimeric antibody with specificity for human b cell surface antigen,a process for the preparation and methods utilizing the same
JP3101690B2 (ja) 1987-03-18 2000-10-23 エス・ビィ・2・インコーポレイテッド 変性抗体の、または変性抗体に関する改良
EP0940468A1 (en) 1991-06-14 1999-09-08 Genentech, Inc. Humanized antibody variable domain
JPH08511420A (ja) 1993-06-16 1996-12-03 セルテック・セラピューテイクス・リミテッド 抗 体
US6074642A (en) 1994-05-02 2000-06-13 Alexion Pharmaceuticals, Inc. Use of antibodies specific to human complement component C5 for the treatment of glomerulonephritis
US6194551B1 (en) 1998-04-02 2001-02-27 Genentech, Inc. Polypeptide variants
ATE375365T1 (de) 1998-04-02 2007-10-15 Genentech Inc Antikörper varianten und fragmente davon
US6737056B1 (en) 1999-01-15 2004-05-18 Genentech, Inc. Polypeptide variants with altered effector function
KR100940380B1 (ko) 1999-01-15 2010-02-02 제넨테크, 인크. 효과기 기능이 변화된 폴리펩티드 변이체
ES2483991T3 (es) 2000-10-10 2014-08-08 Genentech, Inc. Anticuerpos contra C5 que inhibe la activación de las células endoteliales de tipo II
EP1425042B2 (en) 2001-08-17 2016-02-10 Genentech, Inc. Complement pathway inhibitors binding to c5 and c5a without preventing the formation of c5b
ITMI20021527A1 (it) 2002-07-11 2004-01-12 Consiglio Nazionale Ricerche Anticorpi anti componente c5 del complemento e loro uso
US7361740B2 (en) 2002-10-15 2008-04-22 Pdl Biopharma, Inc. Alteration of FcRn binding affinities or serum half-lives of antibodies by mutagenesis
EP3263596A1 (en) 2002-12-16 2018-01-03 Genentech, Inc. Immunoglobulin variants and uses thereof
US20070116710A1 (en) 2004-02-03 2007-05-24 Leonard Bell Methods of treating hemolytic anemia
US20050169921A1 (en) 2004-02-03 2005-08-04 Leonard Bell Method of treating hemolytic disease
KR100891620B1 (ko) 2004-04-13 2009-04-02 에프. 호프만-라 로슈 아게 항-p-셀렉틴 항체
TWI309240B (en) 2004-09-17 2009-05-01 Hoffmann La Roche Anti-ox40l antibodies
HUE066795T2 (hu) 2006-03-15 2024-09-28 Alexion Pharma Inc Paroxysmalis nocturnalis haemoglobinuriában szenvedõ betegek kezelése egy komplement inhibitorral
JP4954326B2 (ja) 2008-04-11 2012-06-13 中外製薬株式会社 複数分子の抗原に繰り返し結合する抗原結合分子
SI2328616T1 (sl) 2008-08-05 2015-08-31 Novartis Ag Sestavki in postopki za protitelesa proti komplementnemu proteinu C5
HRP20230167T1 (hr) 2008-11-10 2023-03-31 Alexion Pharmaceuticals, Inc. Postupci i pripravci za liječenje poremećaja povezanih s komplementom
BR112012022917A2 (pt) 2010-03-11 2017-01-10 Pfizer anticorpos com ligação a antígeno dependente de ph
TWI667257B (zh) 2010-03-30 2019-08-01 中外製藥股份有限公司 促進抗原消失之具有經修飾的FcRn親和力之抗體
US10280215B2 (en) * 2013-01-31 2019-05-07 Seoul National University R&Db Foundation Anti-C5 antibodies and methods of treating complement-related diseases
RU2746356C2 (ru) * 2014-12-19 2021-04-12 Чугаи Сейяку Кабусики Кайся Антитела к с5 и способы их применения
CA2972393A1 (en) * 2015-02-27 2016-09-01 Chugai Seiyaku Kabushiki Kaisha Composition for treating il-6-related diseases
WO2017123636A1 (en) * 2016-01-11 2017-07-20 Alexion Pharmaceuticals, Inc. Dosage and administration of anti-c5 antibodies for treatment
WO2017132259A1 (en) 2016-01-25 2017-08-03 Shire Human Genetic Therapies, Inc. Anti-c5 antibodies with enhanced ph switch
CA3080187A1 (en) * 2017-10-26 2019-05-02 Alexion Pharmaceuticals, Inc. Dosage and administration of anti-c5 antibodies for treatment of paroxysmal nocturnal hemoglobinuria (pnh) and atypical hemolytic uremic syndrome (ahus)
SG11202005181RA (en) * 2017-12-04 2020-07-29 Ra Pharmaceuticals Inc Modulators of complement activity

Also Published As

Publication number Publication date
EP3829628A1 (en) 2021-06-09
TW202019467A (zh) 2020-06-01
SG10202002898RA (en) 2020-05-28
AU2019315213B2 (en) 2024-05-02
PL3829628T3 (pl) 2024-08-19
CN112512563A (zh) 2021-03-16
US20210301004A1 (en) 2021-09-30
HUE067057T2 (hu) 2024-09-28
ES2980137T3 (es) 2024-09-30
KR20200033225A (ko) 2020-03-27
CA3107618A1 (en) 2020-02-06
TW202024128A (zh) 2020-07-01
DE112019003835T5 (de) 2021-05-27
KR20240115904A (ko) 2024-07-26
CR20210103A (es) 2021-03-22
JP6672533B1 (ja) 2020-03-25
MX2021000516A (es) 2021-04-12
EP4445913A2 (en) 2024-10-16
KR20210037743A (ko) 2021-04-06
WO2020027279A1 (en) 2020-02-06
AU2019315213A1 (en) 2021-03-25
JP6672516B2 (ja) 2020-03-25
EP3829628C0 (en) 2024-05-15
JP2020079331A (ja) 2020-05-28
RS65630B1 (sr) 2024-07-31
AU2024205486A1 (en) 2024-08-22
KR20210038697A (ko) 2021-04-07
BR112021001655A2 (pt) 2021-05-04
TWI701041B (zh) 2020-08-11
JP2020019769A (ja) 2020-02-06
IL280475A (en) 2021-03-01
TWI704157B (zh) 2020-09-11
PH12021550226A1 (en) 2021-10-11
KR20200033348A (ko) 2020-03-27
JP2020073608A (ja) 2020-05-14
EP3829628B1 (en) 2024-05-15

Similar Documents

Publication Publication Date Title
HRP20240823T1 (hr) Farmaceutski pripravak, namijenjen upotrebi u liječenju ili sprječavanju bolesti povezane s c5 i postupak liječenja ili sprječavanja bolesti povezane s c5
JP2018141025A5 (hr)
JP2020019769A5 (hr)
Yuri Gasparyan et al. Adverse cardiovascular effects of antirheumatic drugs: implications for clinical practice and research
Vivar et al. Advances in the treatment of rheumatoid arthritis
Villablanca et al. Blocking lymphocyte localization to the gastrointestinal mucosa as a therapeutic strategy for inflammatory bowel diseases
DK1988882T3 (en) PROLONGED SURVIVAL OF A allograft by inhibiting complement activity
Spear et al. NKG2D CAR T‐cell therapy inhibits the growth of NKG2D ligand heterogeneous tumors
KR102365871B1 (ko) C5-관련 질환의 치료 또는 예방용 의약 조성물 및 c5-관련 질환을 치료 또는 예방하기 위한 방법
HRP20231063T1 (hr) Postupci i pripravci namijenjeni inhibiranju eksprimiranja ldha
EP3344772B1 (en) Antagonistic pdl1 aptamers and their applications in cancer therapy
JP2018520094A5 (hr)
KR102321372B1 (ko) 인터류킨-6에 대한 항체 및 그의 용도
CN101939025A (zh) 搔痒症治疗药
EP3349798A1 (en) Therapeutic combinations of a cd19 inhibitor and a btk inhibitor
TaŞKapilioĞLu Recent advances in the treatment for multiple sclerosis; current new drugs specific for multiple sclerosis
KR20160079918A (ko) Vegf 억제제 및 이리노테칸을 함유하는 항종양 조합물
RU2023101857A (ru) Фармацевтическая композиция, предназначенная для применения для лечения или предупреждения связанного с c5 заболевания, и способ лечения или предупреждения связанного с c5 заболевания
JP2022104920A5 (hr)
Bai et al. Biological therapies of inflammatory bowel disease
RU2021104477A (ru) Фармацевтическая композиция, предназначенная для применения для лечения или предупреждения связанного с с5 заболевания, и способ лечения или предупреждения связанного с с5 заболевания
JP2022101535A5 (hr)
EP3280732B1 (en) Antibodies binding to canine vascular endothelial growth factor and uses thereof in treating canine angiogenesis-related diseases
KR20170055473A (ko) 길항 ctla-4 압타머 및 면역 활성의 증진에서의 그의 적용
Lang et al. High-dose intravenous IgG for chronic idiopathic thrombocytopenic purpura in adults